doxorubicin + dacarbazine + gemcitabine + prednisone + PPB

This is a combination chemotherapy regimen consisting of five agents: - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA, inhibits topoisomerase II, and generates free radicals, leading to cytotoxicity in rapidly dividing cells. - **Dacarbazine** is an alkylating agent that methylates DNA, resulting in inhibition of DNA synthesis and function. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis by incorporation into the growing DNA strand and inhibiting ribonucleotide reductase. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it induces apoptosis in certain cancer cell types (notably lymphoid malignancies). - **PPB** could not be definitively identified as a standard chemotherapeutic or supportive care agent from available sources. It may refer to "procarbazine," "polymyxin B," or another compound, but this cannot be confirmed without further context. This specific five-drug combination does not correspond to any widely recognized or standard chemotherapy protocol for lymphoma or sarcoma based on current literature. However, combinations involving subsets of these drugs (such as doxorubicin plus dacarbazine; doxorubicin plus gemcitabine; regimens including prednisone) are used for various cancers such as soft tissue sarcoma and lymphoma[1][2][3][5]. The mechanism of action involves multiple pathways targeting cell proliferation and survival.